Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2015 Genitourinary Cancers Symposium

26 - 28 Feb 2015
Rosen Shingle Creek, Orlando, United States of America
Effectiveness of adjuvant chemotherapy on patients with bladder cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
Effectiveness of adjuvant chemotherapy on patients with bladder cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
2 Mar 2015
ASCO GU 2015 news roundup
Peter Goodwin - ecancer correspondent, London, UK
ASCO GU 2015 news roundup ( Peter Goodwin - ecancer correspondent, London, UK )
28 Feb 2015
Taxane response in prostate cancer may not be influenced by androgen receptor va...
Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA
Taxane response in prostate cancer may not be influenced by androgen receptor variations ( Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA )
28 Feb 2015
Implications of using adjuvant sorafenib and sunitinib in unfavourable renal car...
Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA
Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma ( Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA )
28 Feb 2015
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in loca...
Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma ( Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK )
28 Feb 2015
Expert commentary on emerging research in genitourinary cancer
Dr Chris Parker - The Royal Marsden Hospital, London, UK
Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )
28 Feb 2015
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanc...
Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )
28 Feb 2015
Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic pr...
Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France
Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer ( Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France )
28 Feb 2015
VEGF targeted therapy and chemo an active combination in rapidly progressive ren...
Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015
Impact of statins on survival outcomes in metastatic renal cell carcinoma
Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
Impact of statins on survival outcomes in metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015
Genomic profiling may reveal new drug targets in urothelial carcinoma
Dr Jeffrey Ross - Albany Medical College, Albany, USA
Genomic profiling may reveal new drug targets in urothelial carcinoma ( Dr Jeffrey Ross - Albany Medical College, Albany, USA )
27 Feb 2015
Combination of abiraterone and cabazitaxel in metastatic castration-resistant pr...
Dr Joaquin Mateo - Institute of Cancer Research, London, UK
Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )
27 Feb 2015
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-...
Dr Mohammad Parvez Shaikh - Loyola University Medical Centre, Maywood, USA
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see? ( Dr Mohammad Parvez Shaikh - Loyola University Medical Centre, Maywood, USA )
27 Feb 2015
Is there a role for androgen deprivation therapy combined with radiotherapy in i...
Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada
Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer? ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )
27 Feb 2015
When and whether to conduct endocrine therapy in non-metastatic prostate cancer
Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark
When and whether to conduct endocrine therapy in non-metastatic prostate cancer ( Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark )
27 Feb 2015
High BMI beneficial in kidney cancer
Dr Laurence Albiges - Dana-Farber Cancer Institute, Boston, USA
High BMI beneficial in kidney cancer ( Dr Laurence Albiges - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015
Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial can...
Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA
Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer ( Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA )
27 Feb 2015
New approach to prostate cancer screening
Dr Sanoj Punnen - University of Miami, Miami, USA
New approach to prostate cancer screening ( Dr Sanoj Punnen - University of Miami, Miami, USA )
27 Feb 2015
ASCO GU 2015: Review of the latest data in prostate cancer
Prof Eleni Efstathiou, Prof Charles Ryan, Dr Heather Payne
ASCO GU 2015: Review of the latest data in prostate cancer ( Prof Eleni Efstathiou, Prof Charles Ryan, Dr Heather Payne )
27 Feb 2015
Dose-escalated brachytherapy best treatment for unfavourable-risk localised pros...
Dr Scott Tyldesley - British Columbia Cancer Agency, Vancouver, Canada
Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer ( Dr Scott Tyldesley - British Columbia Cancer Agency, Vancouver, Canada )
26 Feb 2015
Combination of pazopanib and paclitaxel safe in urothelial cancer
Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA
Combination of pazopanib and paclitaxel safe in urothelial cancer ( Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA )
26 Feb 2015
Tackling renal cancer with a combination of autologous immunotherapy and sunitin...
Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA
Tackling renal cancer with a combination of autologous immunotherapy and sunitinib ( Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA )
26 Feb 2015
ASCO GU 2015: Prostate highlights from day one
Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin
ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )
26 Feb 2015
Challenging results from mTOR inhibitors in metastatic clear cell renal cancer
Prof Thomas Powles - Barts Health, London, UK
Challenging results from mTOR inhibitors in metastatic clear cell renal cancer ( Prof Thomas Powles - Barts Health, London, UK )
26 Feb 2015
Metastatic prostate cancer - Interpreting negative trial results
Prof Stephane Oudard and Prof Noel Clarke
Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )
26 Feb 2015